Human Aldose Reductase (AKR1B1) Enzyme

Este producto es parte de AKR1B - Aldo-keto reductase family 1 member B
Product Graph
234€ (10 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Aldose Reductase (AKR1B1) Enzyme
category
Proteins and Peptides
provider
Abbexa
reference
abx073056
tested applications
SDS-PAGE

Description

Aldose Reductase is a recombinant enzyme.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Aldose Reductase (AKR1B1)
Host
E. coli
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Origin
Human
Expression
Recombinant
Purity
> 95% (SDS-PAGE)
Size 1
10 µg
Size 2
50 µg
Size 3
1 mg
Form
Liquid
Tested Applications
SDS-PAGE
Availability
Shipped within 5-10 working days.
Storage
Store at 4 °C if the entire vial will be used within 2-4 weeks. Store at -20 °C for long term storage. For long term storage, it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P15121
Gene ID
231
NCBI Accession
NP_001619.1
OMIM
103880
Alias
AKR1B1,ADR ALDR1,ALR2,AR
Background
Protein AKR1B1
Status
RUO
Note
This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

AKR1B1, also known as aldose reductase, is a key enzyme in the polyol pathway that converts glucose to sorbitol under hyperglycemic conditions. It has a significant role in the pathogenesis of diabetic complications, such as neuropathy, nephropathy, and retinopathy, as sorbitol accumulation induces osmotic stress and oxidative damage. AKR1B1 also metabolizes reactive aldehydes, including lipid peroxidation products like 4-hydroxynonenal (4-HNE), contributing to cellular detoxification under oxidative stress. Its overactivation under diabetic and inflammatory conditions exacerbates oxidative stress and inflammatory signaling pathways. AKR1B1 inhibitors have been developed as potential therapeutic agents for managing diabetic complications. Beyond diabetes, AKR1B1 is involved in steroid metabolism and the detoxification of xenobiotics. It has also been implicated in cancer progression, as its expression is upregulated in some tumors, promoting proliferation and chemoresistance by reducing reactive aldehydes and maintaining cellular redox balance.

Related Products

EH2164

Human AKR1B1 (Aldose reductase) ELISA Kit

Ver Producto
ER1597

Rat AKR1B1 (Aldose reductase) ELISA Kit

Ver Producto
FNab00261

AKR1B1 antibody

This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member catalyzes the reduction of a number of aldehydes, including the aldehyde form of glucose, and is thereby implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. Multiple pseudogenes have been identified for this gene. The nomenclature system used by the HUGO Gene Nomenclature Committee to define human aldo-keto reductase family members is known to differ from that used by the Mouse Genome Informatics database.

Ver Producto